维普期刊资源整合服务平台（V6.5）

50篇 您的检索式：作者名="TYBRING G"

选中清除导出查看参考文献查看引证文献引用追踪共3页首页上一页第1页下一页末页 /3 跳转

	题名	作者	年代	出处	被引量
1	Pharmacokinetics of losartan and its metabolite E-3174 in relation tothe CYP2C9 genotype 显示文摘	YASAR U FORSLUND-BERGENGREN C TYBRING G	2002	Clin Pharmacol Ther2002，71，1：	1
2	Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish White subjects显示文摘	TYBRING G BOTTIGER Y WIDEN J	1997	Clin Pharmacol Ther1997，62，：	1
3	Role of CYP2C9 polymorphism in losartan oxidation 显示文摘	Yasar U Tybring G Hidestrand M	2001	Drug Metab Dispos2001，29，7：	1
4	Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype 显示文摘	YASAR U FORSLUND-BERGENGREN C TYBRING G	2002	Clin Pharrtuwol Ther2002，71，1：	1
5	Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism显示文摘	Sagar M Tybring G Dahl ML	2000	Gastroenterolog2000，119，3：	1
6	Interphenotype differences in disposition and effect on gastrin levels of omeprazole-suitability of omeprazole as a probe for CYP2C19显示文摘	Tybring G Dahl ML Gotharson E Sagar M Seensalu R	1995	Br J Clin Pharmacol1995，39，5：	1
7	Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes显示文摘	YUE QY ZHONG ZH TYBRING G	1998	Clin Pharmacol Ther1998，64，3：	1
8	Phamlacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype显示文摘	Yasar U Forslund-Bergengren C Tybring G	2002	Clin Pharmacol Ther2002，71，1：	1
9	Role of CYP2C9 polymorphism in losartan oxidation 显示文摘	Yasar U Tybring G Hidestrand M	2001	Drug Metab Dispos2001，29，7：	1
10	Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype显示文摘	Yasar U Forslund-Bergengren C Tybring G	2002	Clin Pharmacol Ther2002，71，1：	1
11	Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes显示文摘	Herrlin K Yasui-Furukori N Tybring G	2003	Br J Clin Pharmacol2003，56，4：	1
12	Metabo-lism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes显示文摘	Herrlin K Yasui-Furukori N Tybring G	2003	Br J Clin Pharmacol2003，56，：	1
13	Role of CYP2C9 polymorphism in losartan oxidation 显示文摘	YASAR U TYBRING G HIDESTRAND M	2001	Drug Metab Dispos2001，29，7：	1
14	Metabolism of citalopram enantiomer in CYP2C19/CYP2D6 phentyped panels of healthy Swedes显示文摘	Herrlin K Yasui - Furukori N Tybring G	2003	Br J Clin Pharmacol2003，56，：	1
15	Role of CYP2C9 polymorphism in losartan oxidation 显示文摘	Yasar U Tybring G Hidestrand M	2001	Drug Metab Dispos2001，29，7：	1
16	Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype显示文摘	Chang M Dahl ML Tybring G	1995	Pharmacogenetics1995，5，6：	1
17	Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism显示文摘	TYBRING G DAHL M L	2000	Gastroenterology2000，119，3：	1
18	Interphenotype differences in disposition and effect on gastin levels of orneprazole-suitability of omeprazole as a probe for CYP2C19显示文摘	Chang M Tybring G Dahl ML	1995	Br J Clin Pharmacol1995，39，：	1
19	Metabolism of citalopram enantiomers in CYP2C 19/CYP2D6 phenotyped panels of healthy Swedes显示文摘	Herrlin K Yasui-Furukori N Tybring G	2003	Br J Clin Pharmaeol2003，56，4：	1
20	Role of CYP2C9 polymor- pbism in losartan oxidation 显示文摘	Yasar U Tybring G Hidestrand M	2001	Drug Metab Dispos2001，29，7：	1

返回顶部每页显示：

共3页首页上一页第1页下一页末页 /3 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示